Asthma is a heterogeneous inflammatory disease of the airways that is associated with
airway hyperresponsiveness and airflow limitation. Although asthma was once simply …

Introduction Bronchodilators are the cornerstone of chronic obstructive pulmonary disease
(COPD) therapy and long-acting muscarinic antagonists (LAMAs) as a mono or combination …

Treatment of COPD should reflect the complexity and heterogeneity of the disease and be
tailored to individual patients. Major goals of COPD treatment are symptom reduction and …

Bronchodilators and anti-inflammatory agents are the mainstream treatments in chronic
obstructive and pulmonary disease (COPD) and asthma. The combination of β2 adrenergic …

Background Navafenterol (AZD8871) belongs to a new class of bronchodilator, the single-
molecule muscarinic antagonist and β-agonist, developed for the treatment of COPD. This …

Background Navafenterol (AZD8871) is a dual-pharmacology muscarinic antagonist β 2−
agonist (MABA) molecule in development for the treatment of chronic obstructive pulmonary …

Introduction Chronic obstructive pulmonary disease (COPD) is a prevalent disease of the
airways in which inhaled bronchodilators can be given as monotherapy or fixed dose …

Chronic obstructive pulmonary disease–diagnosis and management of stable disease; a
personalized approach to care, using the treatable traits concept based on clinical …

那伐芬特罗(navafenterol) 是一单分子且同时具备毒蕈碱受体拮抗和β2 受体激动效应的新型
化合物, 正开发用于治疗慢性阻塞性肺疾病和哮喘等慢性阻塞气道疾病. 该药可显著改善肺功能 …

There is evidence that dual bronchodilation is consistently more effective than long-acting
M3 muscarinic acetylcholine receptor (mAChR) antagonists (LAMAs) or long-acting β2 …